Amylin maintained by Merrill Lynch at sell

Amylin Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Thomas McGahren at a sell rating, based on valuation of the stock, following results released of the one-year phase IIb/III data for its oral dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes, showing it marginally missed the endpoint. Amylin shares Thursday were down $0.35, or 1.15%, at $30.15 on volume of 1,349,988 shares versus the three-month running average of 3,772,470 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.